Chapter 84: Drug Therapy for Sexually Transmitted Infections

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook, and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, during the early days of the COVID -19 pandemic, if you looked strictly at the surveillance data, you might have thought we were experiencing this, like, sudden miraculous victory.

Oh, right!

Yeah, and one of the oldest biological battles in human history.

I mean, the numbers for sexually transmitted infections actually dipped.

They did, yeah.

But as clinicians quickly realized,

that dip was a complete illusion.

It wasn't a decline in transmission at all.

It was just a massive drop in testing, you know, and access to care.

We were basically just looking at a huge blind spot.

Exactly.

And the moment the testing resumed, the reality became incredibly clear.

The rates hadn't just bounced back.

They had accelerated.

Yeah, aggressively.

So, welcome to this deep dive.

If you're listening to this right now, you are likely stepping into advanced clinical practice, maybe as a nurse practitioner or a physician assistant student.

Right, and today we're walking through the realities of the clinical battlefield.

Yeah, specifically focusing on the pharmacology of SDIs, just as outlined in Lynn's pharmacotherapeutics.

And the reason this matters so urgently for your future practice is that, more than half of all these new cases are happening in a very specific, very vulnerable demographic.

You have the 15 to 24 -year -olds.

It is a critical demographic,

and the pathogens we're dealing with are just aggressively adapting.

Right.

So, we're going to break down this pharmacological landscape by looking at the clinical challenges as you'll actually see them in the clinic.

Okay, so what's the roadmap for today?

Well, we'll start with the stealth pathogens,

move to the highly resistant threats, and then look at the collateral damage of syndromic infections.

Nice.

And finally, we'll give you a mental framework to anchor all these drug classes so you can make really fast, accurate, evidence -based decisions.

Perfect.

Let's start with the stealth pathogens.

That's Silence Stealer, right?

Chlamydia trachomatis.

Yeah, Chlamydia.

It is the most frequently reported bacterial STI in the U .S., and its absolute superpower is its invisibility.

Yeah, and that invisibility is precisely what makes it so devastating.

Because in many patients, particularly those with a vagina, Chlamydia produces zero noticeable symptoms.

Right.

None at all.

Exactly.

So, the patient doesn't seek treatment.

And this allows the microbe to silently ascend through the cervical oes, moving all the way up into the uterus and the fallopian tubes.

And that is where the architectural damage happens.

Precisely.

The resulting inflammation can lead to severe pelvic inflammatory disease, ectopic pregnancies,

but the most staggering consequence is the tubal scarring.

Oh, yeah.

The numbers on that are terrifying.

They really are.

The CDC estimates that this highly treatable infection causes absolute sterility in up to 50 ,000 patients every single year.

I mean, 50 ,000?

That is an entire stadium full of people losing their reproductive futures to a bug we can cure with, like basic antibiotics.

Right.

Which is exactly why the clinical guidelines lean so heavily on aggressive proactive surveillance.

You do not wait for symptoms.

You just test.

You test.

The standard of care is annual screening for all sexually active cisgender women and transmasculine patients 24 years old and under.

Okay.

So, when you do catch it, what's our primary clinical weapon for uncomplicated infections?

Well, first line choice for adults is doxycycline.

It's a tetracycline antibiotic that essentially halts the bacteria's ability to synthesize proteins.

Right.

However,

clinical pharmacology isn't just about knowing what drug kills what bug.

It's about understanding the specific patient sitting in front of you.

Exactly.

Because doxycycline might be the heavy hitter, but looking at the lifespan alerts in the text, there are times we absolutely can't use it.

Yes.

Like, if you have a pregnant patient, doxycycline is entirely off the table, particularly in the second and third trimesters.

And we aren't just being cautious here.

There's a very specific mechanical reason for this, right?

Yeah.

The mechanism is fascinating, but dangerous.

So, doxycycline strongly binds to calcium.

So, in a developing fetus, that drug will literally seek out the newly forming skeletal system and the teeth.

It physically incorporates itself into the fetal bone matrix.

Oh, wow.

Yeah.

Which can suppress bone growth and cause severe permanent brownish discoloration of the teeth.

So, if we have a pregnant patient with chlamydia, we pivot to azithromycin as the preferred treatment.

Exactly.

Azithromycin is the go -to there.

But let's follow that clinical scenario a step further.

What if the patient wasn't screened, the infection was totally missed, and they go into labor?

Well, that presents a huge risk to the neonate.

About half of infants born to patients with active cervical chlamydia

will acquire the infection as they pass through the birth canal.

Right.

And how does that usually show up?

It typically manifests as neonatal pneumonia, or a very specific conjunctivitis called ophthalmia neonatorum.

And for those neonates, we obviously aren't using doxycycline either.

No, absolutely not.

The standard there is oral or the ramycin to clear the infection.

Okay, got it.

But I want to pause on the pediatric aspect for a second, because, you know, if we see chlamydia in a toddler, say like a three -year -old, my mind immediately goes somewhere very dark.

Yeah.

We aren't just talking pharmacology anymore at that point.

We're talking about legal requirements, child protective services.

That is exactly where your mind needs to go in clinical practice.

While perinatal transmission can linger in very young infants,

if you diagnose chlamydia in a child over the age of two, sexual abuse is overwhelmingly the most likely cause.

Which means your diagnostic evidence has to be basically bulletproof.

Completely bulletproof.

Because the legal implications are paramount, The CDC requires the use of nucleic acid amplification testing, or NAD, because it is definitively accurate.

And then for treatment.

Once it's confirmed, treatment relies on weight -based dosing, typically using erythromycin or azithromycin.

Okay, so chlamydia plays the long silent game.

But the next pathogen on our radar, nigeria gunneria, operates entirely differently.

Oh, completely differently.

It is loud, it is highly visible, and it is actively, like aggressively evolving to fight back.

Gunneria is truly terrifying from a public health standpoint.

While chlamydia numbers dipped briefly during the pandemic lockdowns, gunneria just kept climbing.

Yeah, the text noted a massive 45 % spike between 2016 and 2020.

Right.

And clinically, the presentation really depends on the local anatomy.

In a patient with a penis, you often see a very visible purulent discharge and severe burning upon urination.

But I was struck by the fact that in a patient with a vagina, gonorrheal cervicitis can be surprisingly mild.

It can be.

But if you're listening, do not let a mild local presentation lull you into a false sense of security.

Because it spreads.

Exactly.

Gunneria can breach the local tissues and enter the bloodstream.

And when that happens, you get disseminated gonococcal infection, or DGI.

And that causes massive systemic collateral damage.

We're talking about pustular skin lesions, severe arthritis, and tenosynovitis.

Yes, that intensely painful inflammation of the tendon sheaths.

And it can even migrate to the heart valves or the brain.

It can.

And as a clinician, you also have to actively hunt for the hidden reservoirs.

Pharyngeal infections,

so gonorrhea in the throat from oral sex, are frequently asymptomatic.

Which makes them a massive driver of transmission, because patients have no idea they're infected.

Exactly.

So if you find gonorrhea anywhere on a patient's body, the guidelines strongly encourage you to swab the pharynx as well.

Okay, and this brings us to the actual treatment, which is where the phrase biological arms race really applies.

The text points out that gonorrhea has developed resistance to almost every single antibiotic we've ever used against it.

Yep.

So phonemides, penicillins, tetracyclines, fluoroquinolones, it is mutated to defeat them all.

It is a master class in bacterial evolution.

It's just wild.

So what do we do now?

Well, right now, looking at the current CDC guidelines, we are down to our very last reliable option for a first line defense, which is septriaxome.

A third generation cephalosporin.

Right.

And because we are so terrified of the bacteria mutating to defeat this final drug, the dosing strategy has changed drastically.

Yeah, it's no longer just a one size fits all injection, right?

That dosing requires you to actually calculate based on the patient's physical weight.

Exactly.

The goal is to hit the bacteria with a massive, sustained serum concentration so it doesn't have a chance to survive and mutate.

Overwhelming force.

Overwhelming force.

So for an uncomplicated infection, if your patient weighs under 150 kilograms, you administer a 500 milligram intramuscular injection of septriaxone.

Okay.

But if they weigh 150 kilograms or more, you must double that dose to a full gram.

You have to overwhelm the pathogen entirely.

And just like with chlamydia, we have a strict mandate to protect neonates during delivery, but the stakes with gonococcal ophthalmia are immediately severe.

Yes.

It rapidly destroys eye structures and causes permanent blindness.

Which is why almost every state has a legal mandate requiring providers to instill a prophylactic topical antibiotic into the eyes of every single newborn immediately postpartum.

Right.

And the only approved topical agent is a 0 .5 % rithromycin ophthalmic ointment.

Okay.

Before we move on to the next pathogen, I want to quickly synthesize a running theme here.

Providing safe, person -centered care across the lifespan.

It's so important.

Because as a prescriber,

your do -not -use list is just as important as your primary algorithms.

We already established that doxycycline is completely out for kids and pregnant patients.

Right.

But there is another drug we'll see later, tinnitusol, that carries massive lifespan warnings.

Tinnitusol is crucial to highlight.

Animal studies have shown it may cause congenital anomalies, so it is strictly contraindicated in pregnancy.

But the lactation warning is equally important.

Yes.

If a breastfeeding patient absolutely must take tinnitusol, they cannot just pump and dump for a day.

They must withhold breast milk for the entire duration of the treatment, plus an additional three full days after the final dose clears their system.

That's a huge disruption for a new parent.

Okay.

Keeping those strict pharmacological boundaries in mind, let's look at a pathogen that feels like, I don't know, a ghost from the Victorian era, but has suddenly roared back into modern clinics.

Ah, yes.

Treponema pallidum.

The Spirachat responsible for syphilis.

The resurgence of syphilis is staggering.

The data shows a 52 % overall increase in just a few years.

But the number that should really stop any clinician in their tracks is the 235 % increase in congenital syphilis.

Babies being born with syphilis?

Yes.

It causes massive organ damage, rhinitis, sore, severe bone tenderness.

And the tragedy is that we can prevent this entirely if we recognize the disease in the adult population.

But syphilis is notorious for playing a very deceptive, staged game.

It's the great pretender.

So the primary stage occurs a few weeks after exposure.

The hallmark is the chancre.

A hard, red, protruding sore at the site of entry.

And what makes it so insidious is that it's typically completely painless, right?

Exactly.

Because it doesn't hurt, and because it often hides out of sight, patients ignore it.

And within a few weeks, it heals entirely on its own.

So the patient thinks they're cured.

Right, they think they're fine.

But the spearshit hasn't left, it has just gone deeper.

It uses that time to disseminate through the bloodstream.

And then what happens?

Weeks later, the patient enters secondary syphilis, breaking out in widespread skin lesions, swollen lymph nodes, and flu -like symptoms.

But even this will eventually fade, and the disease enters a latent phase that can last for decades.

Wow.

And then comes the tertiary stage, where it essentially just dismantles the body's infrastructure.

Yes.

It attacks the cardiovascular system, destroying the aorta and heart valves.

And if it invades the central nervous system, which is neurosyphilis, it causes paralysis,

severe psychiatric deterioration, and profound senility.

And we should note that the clinical progression to neurosyphilis is significantly accelerated and more common in individuals who are co -infected with HIV.

That's a really important clinical point, yes.

So what is our weapon against this spearshit?

Because for all the resistance we see with gonorrhea, syphilis is remarkably old school.

It really is.

Penicillin G remains the absolute gold standard across the board.

But the formulation of the penicillin you choose changes drastically depending on where the spearshit is hiding.

Right.

This is a perfect example of pharmacokinetics dictating clinical choice.

For early stage syphilis, you use benzotheme penicillin G, which is an intramuscular depo injection.

Exactly.

It sits in the muscle and slowly, continuously releases the drug over weeks, which is perfect for killing a slow replicating organism throughout the body.

But, and this is a big wude,

but benzotheme penicillin G cannot cross the blood -brain barrier effectively?

No, it can't.

So if a patient has neurosyphilis, that slow muscle drip won't do anything for the brain.

To breach the central nervous system, you must switch to aqueous crystalline penicillin G administered intravenously.

This hits the bloodstream with massive rapid peak concentrations that basically force the drug across the barrier and into the cerebrospinal fluid.

Okay, I want to push back on a clinical reality here, because patient allergies complicate everything.

What if your patient has syphilis, but they tell you they're allergic to penicillin?

Can't we just pivot to doxycycline like we do for so many other things?

Well, it entirely depends on the patient's state.

If you have a non -pregnant adult with early syphilis,

yes, the guidelines allow you to use doxycycline as an alternative.

Okay.

But if that patient's pregnant, or if they have neurosyphilis, the clinical boundary becomes absolute.

You cannot use a backup.

You cannot.

Penicillin is the only drug with a proven reliable track record of preventing fetal demise and reversing central nervous system destruction in these cases.

So what do you do if they're allergic?

If a pregnant patient reports a penicillin allergy, you verify it with a skin test.

If they're truly allergic, you don't just shrug and prescribe doxycycline.

Right.

The clinician must admit the patient to a hospital and execute a highly controlled penicillin allergy desensitization protocol so that the penicillin can be safely administered.

That is how critical this specific drug is to the outcome.

Wow.

It's a powerful reminder that sometimes the standard of care has no compromises.

None at all.

All right.

So shifting gears a bit, let's move from these major bacterial invaders to a different kind of clinical challenge.

Vaginal imbalances, protozoans, and viral infections.

Let's start with bacterial vaginosis, or BV.

Right, BV.

So BV is fundamentally an ecological disaster.

It isn't an STI in the traditional sense of carrying a new foreign invader.

Right.

It's a severe alteration of the normal vaginal microflora, where beneficial lactobacilli are wiped out and opportunistic organisms like Gardnerella vaginalis just overgrow.

And you diagnose this by looking for specific ecological markers.

So a vaginal pH that has spiked above 4 .5, a thin malodorous discharge, and the presence of Clu cells under a microscope.

Clu cells are fascinating.

They're epithelial cells whose borders are completely obscured because they're so densely coated in bacteria.

And there's also the odor test, right?

Yes.

You can confirm the diagnosis by adding a drop of 10 % potassium hydroxide to the secretions, which immediately generates a sharp fishy odor.

To fix the environment, the primary treatments are metronidazole or clindamycin.

You're basically using these drugs to selectively target the anaerobic overgrowth and allow the normal flora to reestablish itself.

Exactly.

And if you use an alternative like secnidazole, you have to remember the strict safety warning animal studies flag it as a major risk.

So it is contraindicated during pregnancy.

Okay, now contrast BV with an actual parasitic invader, trichomoniasis.

This is caused by trichomonas vaginalis, a flagellated protozoan, and it's the most common non -viral STI in the United States.

It is.

It causes a distinct diffuse yellow -green malodorous discharge.

And if you look at a wet mount under a microscope, you will actually see these parasites rapidly darting around the slide.

The treatment is a massive dose of metronidazole or tinnidazole.

But here is the critical patient education piece.

You have to treat the partner simultaneously.

I'll wait.

Because often male partners are completely asymptomatic.

But if they aren't treated, they'll literally just ping -pong the parasite right back to the patient the next time they have intercourse.

Exactly.

You must treat the entire microscopic ecosystem of the partnership, not just the symptomatic patient.

Let's transition to the viral landscape now.

Specifically, genital herpes, caused by herpes simplex virus type 1 and type 2.

The sheer scale is staggering.

More than 50 million Americans are affected.

Yeah.

And unlike the bacterial infections we've discussed, herpes introduces the concept of lifelong latency.

Right.

After the initial painful outbreak of blistering ulcers, the virus doesn't die.

It travels up the sensory nerves and goes dormant in the dorsal root ganglia.

Just hiding out.

Yep.

And it can wake up and travel back down the nerve to cause recurrent outbreaks for the rest of the patient's life.

Which means we need to be incredibly clear about the therapeutic goals of our antiviral drugs, acyclovir, famsiclover, and valacyclover.

Exactly.

These are nucleoside analogs.

They inhibit viral DNA replication, but they do not eliminate the dormant virus in the nerve roots.

They are suppressors, not cures.

We use them to decrease the severity of symptoms, shorten the duration of an active outbreak, and reduce viral shedding.

I want to address a very common, very dangerous clinical myth here.

The text notes that daily suppressive therapy with valacyclover actually decreases the transmission rate of genital herpes.

I can easily see a patient hearing that and assuming they no longer need to use condoms.

Oh, and that assumption leads to massive transmission spikes.

Valacyclover reduces transmission by roughly 50 percent.

That means half the risk is still entirely present.

As a clinician, you must explicitly educate the patient that barrier methods remain absolutely mandatory, regardless of daily antiviral use.

We also have to be hypervigilant regarding pregnancy and HSV.

If a patient goes into labor with an active herpes lesion, the neonate passing through that viral shedding zone faces catastrophic risks.

Unthinkable risks, honestly.

Neonatal herpes can cause rapid blindness,

widespread neurologic destruction, and death.

So what's the protocol?

If there are active lesions at the onset of labor, a cesarean delivery is absolutely required to bypass the birth canal entirely.

Okay, up to this point, we've had the luxury of talking about confirmed pathogens.

But in the real world of clinical practice, you frequently have to treat the patient long before the lab results come back.

Syndromeic management.

Exactly.

Syndromeic management.

A patient presents with agonizing pain in a specific anatomical structure, and you have to deploy antibiotics presumptively based on local epidemiology.

You're treating the collateral damage while guessing the culprit.

Let's look at non -gonococcal urethritis, or NGU.

Okay.

The patient has severe urethral inflammation, and you find white blood cells on the swab, but the test for gonorrhea is negative.

So it's essentially a diagnosis by exclusion.

You presume the culprit is chlamydia, or maybe mycoplasma, and you immediately prescribe doxycycline, or azithromycin if they're pregnant.

Right.

But a far more complex syndromic challenge is pelvic inflammatory disease, or PID.

This is a severe escalating infection involving the uterus, fallopian tubes, and pelvic peritoneum.

There is a fascinating epidemiological twist mentioned in the text regarding PID.

We just established that STI rates are climbing rapidly.

But the incidence of PID has actually plummeted by nearly 40 % in recent years.

How does that make sense?

It's actually a massive victory for preventive medicine.

PID is the end -stage result of untreated infections.

Because clinicians are screening for chlamydia and gonorrhea so aggressively now, we are catching and curing the pathogens early before they have the chance to ascend into the pelvis and cause the syndrome.

That's incredible.

But when PIDs occur, it is a pharmacological nightmare, right?

Because it's rarely just one bug.

Oh, it's a polymicrobial riot.

Gonorrhea, chlamydia, and a host of anaerobic bacteria are all thriving together.

So because it's a polymicrobial party, you need broad -spectrum combination therapy.

A standard outpatient regimen requires a ceftriaxone injection to cover the gonorrhea, a two -week course of doxycyelin to cover the chlamydia, and a two -week course of metronidazole to wipe out the anaerobes.

Now, I noticed a very specific clinical pearl in the inpatient chart for severe PID.

Even if a patient is hospitalized with an IV line in their arm receiving other intravenous antibiotics, the guidelines strongly urge the clinician to give the doxycycline orally.

Why give a poll when you already have IV access?

It is entirely about patient adherence and comfort.

Intravenous doxycycline is highly caustic to the veins.

Oh, really?

Yeah, it causes severe phlebitis and excruciating pain at the infusion site.

By transitioning to oral doxycycline, you spare the patient that agony, which drastically increases the likelihood that they will actually finish the full 14 -day course.

That is the exact kind of clinical reasoning that separates textbook memorization from actual patient care.

Let's quickly hit two more syndromic structures, the epididymis and the rectum.

Acute epididysimitis causes rapid severe testicular pain.

And for standard sexually acquired cases, we assume gonorrhea and chlamydia, so we use ceftriaxone and doxycycline.

But the clinical reasoning must pivot based on a detailed sexual history.

If the patient engages in insertive anal intercourse, the pharmacology changes.

Yes, because the anatomical environment introduces a new threat,

enteric bacteria from the gastrointestinal tract, like E.

coli.

And doxycycline won't reliably clear those.

Exactly, so the clinician must swap it for a fluoroquinolone like levofloxacin to target the enteric bugs alongside the ceftriaxone.

Finally, we have proctitis inflammation of the rectum, typically presenting with anorectal pain and discharge after receptive anal intercourse.

The presumptive treatment is identical.

Ceftriaxone and doxycycline.

But again, physical assessment drives the pharmacology.

If you examine the patient and find perianal ulcers, you cannot just treat for bacteria.

You must presume a viral co -infection and proactively add an antiviral like a cyclover to target herpes simplex.

So we have traversed a massive pharmacological landscape today.

The sheer number of drug names and combinations can feel incredibly overwhelming when you're prepping for the clinic.

The authors of the text anticipated that, thankfully.

At the very end of chapter 84, they provide a brilliant conceptual tool.

Instead of memorizing drugs by the disease, you need to mentally groot your therapeutic arsenal by drug class.

It builds a far more resilient clinical framework.

Let's outline those four major pillars right now.

Sounds good.

First, your macrolides, specifically azithromycin and erythromycin.

Think of these as your pediatric and pregnancy saviors.

When doxycycline is too dangerous for developing bones, the macrolides step in to clear chlamydia and neonatal infections safely.

Spot on.

The second pillar is your cephalosporins, specifically cefriaxone.

This is your heavy artillery.

Whether it's a simple urethritis or severe pelvic inflammatory disease, cefriaxone is the foundational weapon against the highly resistant, heavily armored threat of gonorrhea.

Third, your nitromidazoles, metronidazole, and tinnidazole.

These are your terraformers.

When you need to alter a toxic microenvironment like bacterial vaginosis or eradicate a parasite like trichomonas, these drugs destroy the anaerobic invaders from the inside out.

And the final pillar, your antiviral drugs, acyclovir, famsiclovir, and valacyclovir.

These are the suppressors.

They will never cure the patient, but they keep the lifelong latency of herpes simplex in check, reducing shedding and providing systemic relief.

Grouping the pharmacology like that makes the clinical logic so much clearer.

But as we wrap up this deep dive, I want to leave you, our listener, with a clinical puzzle to mull over.

We spent a lot of time discussing the terrifying adaptability of Neisseria gonorrhea.

Yeah?

It has defeated every class of antibiotic we have ever thrown at it, save one.

Right now, cefriaxone stands entirely alone as the last reliable first -line defense.

We're literally using massive weight -based doses just to maintain that high ground.

Which raises an incredibly sobering question for your future practice.

It isn't a matter of if, but when.

How will the clinical landscape shift when this final cephalosporin fails?

What exactly happens in our clinics and in our communities when the resistant threat finally outmaneuvers our ultimate weapon?

It's a question that perfectly highlights why precise, evidence -based prescribing isn't just about passing an exam.

It's about preserving the very few effective tools we have left in this microscopic arms race.

Because the moment we stop adapting, the moment we stop learning the pharmacology inside and out, is the moment the pathogens win.

Thank you for joining us on this deep dive today.

On behalf of the Last Minute Lecture Team, keep asking the hard questions, keep thinking critically, and we wish you the absolute best in your clinical practice.

Keep fighting the good fight out there.